Author: Tan, Jiahong; Yuan, Yuan; Xu, Cheng; Song, Chunyan; Liu, Dan; Ma, Ding; Gao, Qinglei
Title: A retrospective comparison of drugs against COVID-19 Cord-id: hjob0kp2 Document date: 2020_12_14
ID: hjob0kp2
Snippet: Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly re
Document: Coronavirus disease 19 (COVID-19) has posed serious threats to the general population. To relieve the crisis, a comparison of drug effects against COVID-19 is instructive. Between January 27, 2020 and March 21, 2020, a total of 333 patients treated with arbidol, corticosteroids, hydroxychloroquine, lopinavir/ritonavir, or oseltamivir monotherapy, having definite outcomes and serological antibody detection results, were retrospectively analyzed. The hydroxychloroquine group had a significantly reduced duration of hospital stay than the arbidol and corticosteroids groups. The oseltamivir group had a significantly shorter length of hospital stay than the arbidol, corticosteroids, and lopinavir/ritonavir groups. The hydroxychloroquine group had a significantly higher IgM titer than the other four groups and exhibited significantly higher IgG levels than the arbidol, lopinavir/ritonavir, and oseltamivir groups. Our findings indicated that hydroxychloroquine might have the potential for efficient COVID-19 management, while oseltamivir should be prudently considered in combination therapy.
Search related documents:
Co phrase search for related documents- absorption improvement and lopinavir ritonavir: 1, 2
- absorption improvement and lopinavir ritonavir arbidol: 1, 2
- absorption improvement and lopinavir ritonavir group: 1, 2
- acid detection and acute respiratory distress syndrome: 1, 2, 3, 4, 5
- acid detection and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acid detection and lopinavir ritonavir: 1, 2, 3
- acid detection result and acute respiratory syndrome: 1, 2
- acute respiratory distress syndrome and additional investigation: 1
- acute respiratory distress syndrome and administration rate: 1, 2
- acute respiratory distress syndrome and lopinavir arbidol: 1
- acute respiratory distress syndrome and lopinavir oseltamivir: 1, 2, 3
- acute respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory distress syndrome and lopinavir ritonavir arbidol: 1
- acute respiratory distress syndrome and lopinavir ritonavir group: 1
- acute respiratory distress syndrome and lopinavir ritonavir monotherapy: 1
- acute respiratory distress syndrome and lopinavir ritonavir oseltamivir: 1
- acute respiratory distress syndrome patient and lopinavir ritonavir: 1
- acute respiratory syndrome and additional investigation require: 1, 2
- acute respiratory syndrome and lopinavir ritonavir oseltamivir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
Co phrase search for related documents, hyperlinks ordered by date